Akeso begins patient enrolment in phase I trial of AK138 D1 for the treatment of advanced malignancies in Australia: Hong Kong Saturday, March 1, 2025, 12:00 Hrs [IST] Akeso, Inc.

Goldman Sachs analyst Salveen Richter initiated coverage of Summit Therapeutics (SMMT) with a Buy rating and $42 price target a Summit’s lead ...

Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the treatment ...

Summit Therapeutics (NASDAQ:SMMT – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC ...

Ivonescimab, the new drug, was found in a trial conducted in China to have bested Keytruda, the blockbuster medication ...

Chinese biotech company Akeso developed a lung cancer drug Ivonescimab, which outperformed Merck's Keytruda in trials. This ...

China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price. But this disruptive trend isn’t confined to Big Tech: It has been quietly happening in ...

Q4 2024 Earnings Call Transcript February 24, 2025 Operator: Good morning and welcome to Summit Therapeutics Fourth Quarter and Year End 2024 Earnings and Update Call. All participants will be in ...

Pfizer has partnered with Summit Therapeutics to evaluate ivonescimab, a PD-1/VEGF bispecific antibody, in combination with ...

Summit Therapeutics established a clinical trial collaboration with Pfizer to develop ivonescimab for NSCLC and solid tumors.